The Cost of Epilepsy in the United States: An Estimate from Population‐Based Clinical and Survey Data

Abstract

Direct costs attributable to epilepsy are below previous estimates. Indirect costs adjusted for the socioeconomic conditions of patients are above previous estimates. Findings indicate that epilepsy is unique in the large proportion of costs that are productivity-related, justifying further investment in the development of effective interventions.